The concept of adoptive NK cell cancer immunotherapy to fight cancer was proven a decade ago from pioneering clinical studies against hematological malignancies.
Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy.
Because of their ability to kill tumor cells, NK cells are an attractive target for cancer immunotherapies. We want to use the best that nature and the human immune system have to offer . For this, NK cells are a very logical candidate. They are considered safer than T cells, and can be offered off-the-shelf and are available to patients as soon as they are needed.